Welcome to our dedicated page for GeneDx Holdings news (Ticker: WGS), a resource for investors and traders seeking the latest updates and insights on GeneDx Holdings stock.
GeneDx Holdings Corp. (Nasdaq: WGS), commonly referred to as GeneDx, regularly issues news focused on rare disease genomics, clinical impact, and corporate developments. The company describes itself as the global leader in rare disease diagnosis and a pioneer in genomic medicine, emphasizing the role of exome and genome sequencing and its GeneDx Infinity dataset in transforming care.
News updates from GeneDx often highlight financial results and guidance, including revenue trends, exome and genome test volumes, and margin profiles, alongside commentary on how these metrics relate to the company’s growth in genomic testing. Earnings releases may be accompanied by details on conference calls and investor presentations.
GeneDx also publishes frequent announcements on scientific and clinical milestones. These include peer‑reviewed publications, participation in large genomic newborn screening programs such as GUARDIAN and BEACONS, and recognition of its research by major medical journals. The company’s news flow covers conference presentations, advances in rapid genome sequencing, and developments in long‑read sequencing and gene–disease discovery.
Additional news items describe new test offerings like GenomeDx Prenatal, leadership appointments in medical and business roles, and partnerships such as the collaboration with Komodo Health to link GeneDx Infinity with real‑world healthcare data. For readers following WGS, this news page provides a centralized view of GeneDx’s financial disclosures, research output, clinical initiatives, and strategic collaborations in rare disease genomics.
GeneDx Holdings Corp. (Nasdaq: WGS) has priced an offering of 428,571,429 shares of Class A common stock at $0.35 per share, totaling anticipated gross proceeds of $150 million. The offering comprises 328,571,429 shares through an underwritten public offering and 100,000,000 shares via a registered direct offering to institutional investors. The direct offering includes shares subject to stockholder approval to meet Nasdaq requirements. The funds will primarily be used for general corporate purposes, including working capital, debt repayment, and strategic investments. The closings are scheduled for January 31, 2023, pending customary conditions.
GeneDx Holdings Corp. (Nasdaq: WGS) announced plans for an underwritten public offering of its Class A common stock, with an expected total gross proceeds of approximately $150 million. The offering will include a 30-day option for the underwriter to purchase an additional 15% of the shares. Concurrently, GeneDx will offer shares to institutional investors affiliated with its board members. The proceeds from these offerings will primarily fund general corporate purposes such as working capital, debt repayment, and strategic investments. Jefferies is the book-running manager for the public offering.